Document:

Exhibit 10.16

                              INTELLECTUAL PROPERTY
                               SECURITY AGREEMENT

     INTELLECTUAL PROPERTY SECURITY AGREEMENT made this first day of August,
2002, by and between ROCKWELL CAPITAL PARTNERS, LLC, a Delaware limited
liability company, having an office at 488 Madison Avenue, 8th Floor, New York,
New York 10022, as secured party ("Secured Party") and INFORMEDIX, INC., a
Delaware corporation having offices at Georgetown Park, 5880 Hubbard Drive,
Rockville, Maryland 20852-4821, as debtor ("Debtor").

     In consideration of the mutual covenants hereinafter set forth and other
valuable consideration, receipt of which is hereby acknowledged by Debtor, and
to induce Secured Party to advance money to Debtor as working capital pursuant
to the terms of one or more Convertible Promissory Notes (the "Notes"), the
parties hereto agree as follows:

     1. Grant of Security Interest: Assignment of Proceeds. Debtor hereby grants
to Secured Party a continuing security interest in and assigns, pledges and
transfers to Secured Party the following collateral (hereinafter collectively
called "Collateral"):

          (a) All patents, patent applications and patentable inventions,
including, without limitation, the Debtor's Pioneer Patent Portfolio, each such
patent being identified in Schedule I attached hereto and made a part hereof and
each patent application identified in such Schedule I, and including, without
limitation, (i) all inventions and improvements described and claimed therein
and the right to make, use or sell the same, (ii) the right to sue or otherwise
recover for any misappropriations thereof, (iii) all income, royalties, damages
and other payments now and hereafter due and/or payable with respect thereto
(including, without limitation, payments under all licenses entered into in
connection therewith, and damages and payments for past and future infringements
thereof), and (iv) all rights corresponding thereto throughout the work and all
reissues, divisions, continuations, continuations-in-part, substitutes, renewals
and extensions thereof, all improvements thereon and all other rights of any
kind whatsoever of each Grantor accruing hereunder or pertaining thereto (the
"Patents").

          (b) All license agreements (subject to the rights of the other parties
thereto) with any other person in connection with any of the Patents, or such
other person's patents, trade names, trademarks, service marks, copyrights or
works of authorship, or other intellectual property, whether such grantor is a
licensor or licensee under any such license agreement, including, without
limitation, the license agreements listed on Schedule II attached hereto and
made a part hereof, and any right to prepare for sale, sell and advertise for
sale, a!! goods and/or services now or hereafter owned by the Grantor and now or
hereafter covered by any such licenses (the "Licenses"); provided, however, that
to the extent that the consent of any other party to any of the Licenses is
required, under the terms thereof, for the collateral assignment thereof, this
Agreement shall not effect any collateral assignment of(or otherwise be applied
so as to cause a default under) such Licenses.

          (c) All proceeds of the Accounts, Patents and Licenses, including,
without limitation, all claims by Debtor against third parties for infringement
of the Patents or Licenses (at! hereinafter called the "Proceeds").

<PAGE>

     The Collateral shall secure the amounts from time to time due from Debtor
to Secured Party whether on an open-account basis or evidenced by the Notes or
otherwise (all hereinafter called "Obligations").

     2. Warranties. Debtor represents and warrants as follows:

          (a) Debtor is duly organized and existing under the laws of the State
of Delaware and is duly qualified to do business in every other state in which
it does business. The execution, delivery and performance of this Security
Agreement are within Debtor's corporate powers, have been duly authorized, are
not in contravention of law or the terms of Debtor's charter, by-laws or other
corporate papers, or of any indenture, agreement or undertaking to which Debtor
is a party or by which it is bound.

          (b) Except for the security interests granted hereby, and the Security
interest granted to the Warren & Lewis Investment Corporation which is superior
to this security interest, which may include Warren & Lewis, Private Investors
Equity, LLC, and others; or subsequently permitted pursuant to the terms hereof,
the Collateral currently existing or to be acquired hereafter is and will be
lawfully owned by Debtor, free from any adverse lien or encumbrance, and Debtor
has the right to grant Secured Party a security interest in the Collateral; and
Debtor will defend the Collateral or any part thereof against claims and demands
of any person at any time claiming any interest therein.

          (c) With respect to the Patents and the Licenses:

              (i) Debtor has not made any pervious assignment, transfer or
agreement constituting a present or future assignment, transfer or encumbrance
of any of the Patents or Licenses (except for any which is immaterial to the
business of such Debtor). Debtor intends to give a first lien securities
interest to the Warren & Lewis Investment Corporation for up to $350,000 of debt
as part of a planned Bridge Loan transaction. Except as set forth on Schedule I
or II nor has Debtor granted any License other than those listed on Schedule II
hereto, release, covenant not to sue, or non-assertion assurance to any person
with respect to any part of Patents or Licenses (except for any which is
immaterial to the business of Debtor;

              (ii) Debtor has used proper statutory notice in connection with
its use of each patent;

              (iii) This Agreement creates in favor of the Secured Party a valid
subordinated security interest in the Patents and Licenses;

              (iv) Except as set forth in Schedule I or II hereof, and any
required consent of other parties to Licenses, no consent of any person and no
authorization, approval or other action by, and no notice to or fling with, any
governmental authority or regulatory body or other person is required (i) for
the grant by Debtor of the assignment and security interest granted hereby, for
the pledge by Debtor of the Patents or Licenses pursuant hereto, or for the
execution, delivery or performance of this Agreement by Debtor, (ii) for the
perfection or maintenance of the pledge, assignment and security interest
created hereby (including the subordinated nature of such pledge, assignment and
security interest), except for the filing of financing and continuation

<PAGE>

statements under the Uniform Commercial Code, which financing statements have
been duly filed, and the filing and recording of this Agreement in the United
States Patent and Trademark Office against each patent or patent application, or
(iii) for the exercise by the Secured Party of its rights provided for in this
Agreement or the remedies in respect of the Patents or Licenses pursuant to this
Agreement. To the extent that of the Licenses entered into after the date hereof
is material to the business of the subject Debtor or accounted for or could
reasonable be expected to account for more than $50,000 in gross revenues to the
Debtor during Debtor's current or subsequent fiscal year, the Debtor will
hereafter promptly use its commercially reasonable efforts (without being
required to incur any unreasonable expense) to obtain any required third party
consent for the assignment of such License hereunder; and

              (v) Except as set forth on Schedule I or II hereto no claim has
been made to or by Debtor arid is continuing or threatened to or by Debtor that
any Patents and Licenses (except that which is immaterial to such Debtor's
business) is invalid or unenforceable or that the use by Debtor of any Patents
and Licenses (except that which is immaterial to such Debtor's business) does or
may violate the rights of any person. To the best of Debtor's knowledge, there
is currently no infringement or unauthorized use of any Patents and Licenses
(except that which is immaterial to such Debtor's business) or could not
reasonably be expected to result in a claim or claiming against such Debtor for
amounts exceeding $25,000 individually or in the aggregate.

     3.   Place of Business arid Location of Record Keeping; Reports.

          (a) All Records will be kept at Debtor's premises stated above, unless
Secured Party shall otherwise consent in writing.

          (b) Debtor shall, upon the request of Secured Party, render to Secured
Party periodic reports of the Accounts, the Patents, the Licenses or Proceeds
arising therefrom.

          (c) Debtor shall at all reasonable times and from time to time allow
Secured Party by or through any of its officers, agents, attorneys or
accountants, to examine or inspect the Inventory wherever located and to
examine, inspect and make extracts front the Records and to arrange for
verification Of Accounts directly with the respective Account debtors.

          (d) Debtor shall do, make, execute and deliver all such additional and
further acts, things, deeds, assurances and instruments as Secured Party may
require more completely to vest in and assure to Secured Party its rights
hereunder or in any Collateral.

      4. Preservation and Disposition of Collateral; Limited Agreement of
Subordination.

          (a) Debtor shall keep the Collateral free from any adverse lien,
encumbrance or security interest. Notwithstanding the foregoing, Secured Party
agrees that Debtor may pledge the Collateral to Warren & Lewis or its affiliates
company on a first priority basis as to security and as to payment up to a
maximum loan amount of $350,000.

          (b) At its option, Secured Party may discharge taxes, liens, security
interests or other encumbrances at any time levied or placed on the Collateral,
Debtor agrees to reimburse

<PAGE>

Secured Party, on demand, for any payment made, or any expense incurred by
Secured Party pursuant to the foregoing authorization.

          (c) Until default, Debtor may use the Patents in any lawful manner not
inconsistent with this Agreement and may also issue Licenses in the ordinary
course of business, for standard royalty rates; provided, however, that any and
all Proceeds of any such sale shall be fully and faithfully accounted for. A
License in the ordinary course of business does not include a transfer in
partial or total satisfaction of a debt nor does it include a bulk transfer or
sacrifice sate.

          (d) Upon a default, at the request of Secured Party, Debtor will
deliver to Secured Party lists or copies of the Patent and License related
Accounts promptly after they arise, and will deliver to Secured Party, promptly
upon receipt, all Proceeds received by Debtor, including all Proceeds of the
Accounts, in the exact form in which they are received. To evidence Secured
Party's rights hereunder, Debtor will assign or endorse these Intellectual
Property related proceeds to Secured Party as Secured Party may request and
Secured Party shall have full power to collect, compromise, endorse, sell, or
otherwise deal with the Accounts in its own name or that of Debtor. Secured
Party in its discretion may apply cash proceeds to the payment of any
Obligations secured hereby or may release such cash proceeds to Debtor for use
in the operation of Debtor's business.

          (e) Secured Party may upon a default notify the Account debtors or
other obligors that the Accounts have been assigned to Secured Party and should
be paid to Secured Party. Upon default, the request of Secured Party, Debtor
shall so notify its Account debtors and indicate on alt invoices to such Account
debtors that the Accounts are payable to Secured Party. So long as such notices
of assignment shall not have been given to the Account debtors or the obligors,
Debtor shall have the authority to ask for, demand, collect, institute and
maintain suits in its own name for, receive, compromise and give acquittances
for, any and all sums which are now or may hereafter become due on the Accounts.

     5.   Financing Statements.

          (a) At the request of Secured Party, Debtor will join with Secured
Party in executing one or more financing statements pursuant to the Unifo
Commercial Code in form satisfactory to Secured Party and will pay the cost of
filing the same in all public offices wherever filing is deemed by Secured Party
to be necessary or desirable.

          (b) Without the written consent of Secured Party, Debtor will not
allow any adverse financing statement covering the Collateral or any part
thereof to be on file in any public office~

     6.   Events of Default, Acceleration. Any or all unpaid principal and
interest shall at the option of Secured Party and notwithstanding any time or
credit allowed by any instrument evidencing a liability, including but not
limited to invoices of Secured Party for goods, become immediately due and
payable without notice or demand upon the occurrence of any of the following
events of default:

<PAGE>

          (a) The dissolution of Debtor or any vote in favor thereof by the
board of directors and shareholders of Debtor; or

          (b) Debtor makes an assignment for the benefit of creditors, or files
with a court of competent jurisdiction an application for appointment of a
receiver or similar official with respect to it or any substantial part of its
assets, or Debtor files a petition seeking relief under any provision of the
Federal Bankruptcy Code or any other federal or state statute now or hereafter
in effect affording relief to debtors, or any such application or petition is
filed against Debtor, which application or petition is not dismissed or
withdrawn within sixty (60) days from the date of its filing; or

          (c) Debtor fails to pay the principal amount, or interest on, or any
other amount payable under, its Note to Secured Party this Note of even date
herewith as and when the same becomes due and payable; or

          (d) Debtor admits in writing its inability to pay its debts as they
mature; or

          (e) Debtor sells all or substantially all of its assets or merges or
is consolidated with or into another corporation except a merger with or into a
publicly traded corporation; or

          (f) A proceeding is commenced to foreclose a security interest or lien
in any property or assets of Debtor as a result of a default in the payment or
performance of any debt ($15,000) of Debtor or of any subsidiary of Debtor; or

          (g) A final judgment for the payment of money in excess of$ 15,000 is
entered against Debtor by a court of competent jurisdiction, and such judgment
is not discharged (nor the discharge thereof duly provided for) in accordance
with its terms, nor a stay of execution thereof procured, within thirty (30)
days after the date such judgment is entered, and, within such period (or such
longer period during which execution of such judgment is effectively stayed), an
appeal therefrom has not been prosecuted and the execution thereof caused to be
stayed during such appeal; or

          (h) An attachment or garnishment is levied against the assets or
properties of Debtor or any subsidiary of Debtor involving an amount in excess
of$ 15,000 and such levy is not vacated, bonded or otherwise terminated within
thirty (30) days after the date of its effectiveness; or

          (i) Debtor defaults in the due observance or performance of any
covenant, condition or agreement on the part of Debtor to be observed or
performed pursuant to the terms of this Note (other than the default specified
in paragraph 6(c) above) and such default continues uncured for a period of
thirty (30) days; or

          (j) Debtor defaults in the payment (regardless of amount) when due of
the principal of, interest on, or any other liability on account of, any
indebtedness of Debtor having a face or principal amount in excess of $15,000,
or a default occurs in the performance or observance by Debtor of any covenant
or condition (other than for the payment of money) contained in any note or
agreement evidencing or pertaining to any such indebtedness, which

<PAGE>

causes the maturity of such indebtedness to be accelerated or permits the holder
or holders of such indebtedness to declare the same to be due prior to the
stated maturity thereof; or

          (k) Debtor does not proceed with a reverse takeover into a public
shell by the Maturity Date for any reason whatsoever.

     7.   Rights and Remedies on Default.

          (a) Upon the occurrence of any event of default, and at any time
thereafter, Secured Party shall have the rights and remedies of a secured party
under the Uniform Commercial Code of the State of New York in effect from time
to time (the "N.Y. Uniform Commercial Code") in addition to the rights and
remedies provided herein or in any other instrument or paper executed by Debtor.
Secured Party may enter into the premises of Debtor and repossess the Collateral
or may require Debtor to assemble the Collateral and make it available to
Secured Party at a place to be designated by Secured Party which is reasonably
convenient to all parties. Secured Party will give Debtor reasonable notice of
the time and place of any public sale thereof or of the time after which any
private sale or other intended disposition thereof is to be made. Any such sale
shall be under the advice and assistance of an investment-banking firm familiar
with the disposition of intellectual property. The requirement of reasonable
notice shall be met if such notice is mailed, postage prepaid, to the address of
Debtor first set forth above, or as modified by any notice given pursuant to
this Agreement, at least five days before the time of the sale or disposition.
Debtor shall pay to Secured Parts' on demand any and all reasonable expenses,
legal expenses and reasonable attorneys' fees, incurred or paid by Secured Party
in protecting or enforcing the obligations arid other rights of Secured Party
hereunder including its right to take possession of the Collateral. Insofar as
Collateral shall consist of the Intellectual property related Accounts, Secured
Party may demand, collect, receipt for, settle, compromise, adjust, due for,
foreclose or realize upon such Accounts as Secured Party may determine whether
or not such Accounts are then due and, for the purpose of realizing Secured
Party's rights therein, Secured Party may receive, open and dispose of mail
addressed to Debtor and endorse notes, checks drafts, money orders, documents of
title or other evidences of payment, shipment or storage or any form of such
Accounts on behalf of and in the name of Debtor.

          (b) The Secured Party may exercise in respect of the Patents and
Licenses, in addition to other rights and remedies provided for herein or in any
other loan document or otherwise available to it, all the rights and remedies of
a Secured Party upon default under the N.Y. Uniform Commercial Code (whether or
not the N.Y. Uniform Commercial Code applies to the affected Patents and
Licenses) and also may (i) require any and all of the Debtor to and hereby
agrees that it will at its expense and upon request of the Secured Party
forthwith, assemble all or part of the documents and things embodying any part
of the Patents and Licenses as directed by the Secured Party and make them
available to the Secured Party at a place and time to be designated by the
Secured Party; (ii) without notice except as specified below and as required by
law, sell the Patents and Licenses or any part thereof in one or more parcels at
public or private sale, at any of the Secured Party's offices or elsewhere, for
cash, on credit or for future delivery, and upon such other terms as the Secured
Party may deem commercially reasonable; and (iii) occupy any premises owned or
leased by any Debtor where documents and things embodying the Patents and
Licenses or any part thereof are assembled or located for a reasonable

<PAGE>

period in order to effectuate its rights and remedies hereunder or under law,
without obligation to Debtor in respect of such occupation. Any such sale shall
be under the advice and assistance of an investment-banking firm familiar with
the disposition of intellectual property. In the event of any sale, assignment,
or other disposition of any of the Patents and Licenses, the goodwill of the
business connected with and symbolized by any of the Patents and Licenses
subject to such disposition will be included, and Debtor will supply to the
Secured Party or its designee Debtor's know-how and expertise, and documents and
things embodying the same, relating to the manufacture, distribution,
advertising and sale of products or the provisions of services relating to any
Patents and Licenses subject to such disposition and, including, but not limited
to, Debtor's customer lists and other records and documents relating to such
Patents and Licenses and to the manufacture, distribution, advertising and sale
of such products and services. Debtor agrees that, to the extent notice of sale
shall be required by law, at least ten (10) days written notice to Debtor of the
time and place of any public sale or the time after which any private sale is to
be made will constitute reasonable notification. The Secured Party shall not be
obligated to make any sale of Patents and Licenses regardless of notice of sale
having been given. The Secured Party may adjourn any public or private sale from
time to time by announcement at the time and place fixed therefore, and such
sale may, without further notice except as required by law, be made at the time
and place to which it was so adjourned.

          (c) Subject to the priority interest of Warren & Lewis, all cash
proceeds received by the Secured Party in respect of any sale of, collection
from, or other realization upon, all or any part of the Patents and Licenses
may, in the discretion of the Secured Party, be held by the Secured Party as
collateral for, and/or then or at any time thereafter applied (after payment of
any amounts payable to the Secured Party), in whole or in part to costs of such
sale, hereunder. Any surplus of such cash or cash proceeds held by the Secured
Party remaining after payment in full of all of the Obligations shall be paid
over to the Debtor or to whoever may be lawfully entitled to receive such
surplus.

     8.   General.

          (a) No Waiver. Secured Party shall not be deemed to have waived any of
Secured Party's rights hereunder or under any other agreement, instrument or
paper signed by Debtor unless such waiver be in writing and signed by Secured
Party. No delay or omission on the part of Secured Party in exercising any right
shall operate as a waiver of such right or any other right. A waiver on any one
occasion shall not be construed as a bar to or waiver of any right or remedy on
any future occasion. All of Secured Party's rights and remedies, whether
evidenced hereby or by any other agreement, instrument or paper, shall be
cumulative and may be exercised singularly or concurrently.

          (b) Notices. All demands upon Debtor and all notices given hereunder
shall be in writing and shall be effective when delivered in person or when
deposited in the mails by first class mail, postage prepaid addressed to the
appropriate party at addresses first set forth above, or at such other address
as either party may hereafter indicate by notice duly given in accordance with
this paragraph, or

          (c) Governing Law. This Agreement shall be governed by and construed
in accordance with the laws of the State of New York, without regard to its
choice of law rules.

<PAGE>

          (d) Severability. Any provision hereof which may prove unenforceable
under any law shall not affect the validity of any other provision hereof.

          (e) Successors. All the provisions of this Agreement shall be binding
upon and inure to the benefit of and be enforceable by the respective successors
and assigns of the parties hereto. If at any time or times by assignment or
otherwise Secured Party transfers any obligations and Collateral, such transfer
shall carry with it Secured Party's powers and rights under this Agreement with
respect to the obligations and collateral transferred and the transferee shall
become vested with said powers and rights, whether or not they are specifically
referred to in the transfer.

          (f) Counterparts. This Agreement may be executed simultaneously in two
or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument.

          (g) Options. The captions confined in this Agreement are for reference
purposes only and are not part of this Agreement.

          (h) Entire Agreement; Interest. This Agreement contains the entire
agreement of the parties hereto with respect to the grant of the security
interest in the Inventory and the Accounts and the assignment of the proceeds
thereof and supersedes all prior written agreements, negotiations, and oral
understandings, if any, with respect thereto.

     IN WITNESS WHEREOF, each of the parties hereto has executed this

     Agreement, on the day first above mentioned, by their respective officers,
thereunto authorized.

                                        ROCKWELL CAPITAL PARTNERS

                                        By: /s/ Robert DePalo
                                           --------------------------------

                                        INFORMEDIX, INC.

                                        By: /s/ Bruce Kehr
                                           --------------------------------

<PAGE>

                                   SCHEDULE I
                                   ----------

                               INFORMEDIX PATENTS
                              UNITED STATES PATENTS
<TABLE>
<CAPTION>
Date Filed      Ref. No.                            Title                           Status       Country
----------      --------                            -----                           ------       -------
<S>            <C>                <C>                                               <C>          <C>
8/30/84        4,768,176          Apparatus for Alerting a patient to Take          Issued         United
                                  Medication                                        8/30/88        States

8/30/84        4,768,177          Method and Apparatus for Alerting a Patient to    Issued         United
                                  Take Medication                                   8/30/88        States

1/17/90        5,200,891          Electronic Medication Dispensing Method           Issued 4/6/93  United
                                                                                                   States

7/23/90        5,752,235          Electronic Medication Monitoring and Dispensing   Issued         United
                                  Method                                            5/12/98        States

12/02/94       5,642,731          Method of and Apparatus for Monitoring the        Issued         United
                                  Management of Disease                             7/1/97         States

3/7/97         60,040,128         Automatic Adjustment of Treatment Regimen         Incorporated   United
                                                                                    Into PCT       States
                                                                                    Application

4/18/97        60,044,472         Wireless Method and Apparatus for Monitoring      Incorporated   United
                                  Disease                                           Into PCT       States
                                                                                    Application

7/1/97         60,051,389         Method and Apparatus for Communication Between    Incorporated   United
                                  Fixed and Mobile Medication Dispensers and        Into PCT       States
                                  Disease Management Tools                          Application

9/8/97         5,954,641          Method, Apparatus, and Operating System for       Issued         United
                                  Managing the Administration of Medication and     9/21/99        States
                                  Medical Treatment Regimens

10/22/97       08,955,952         Variable Capacity Medication Trays and Labeling   Incorporated   United
                                  Method                                            Into PCT       States
                                                                                    Application

12/22/97       60,068,473         Second Wireless Provisional Application And       Incorporated   United
                                  Assay Algorithms                                  Into PCT       States
                                                                                    Application

3/6/98         PCT/US 98/03933    Method, Apparatus, and Operating System for       Pending        United
                                  Real-Time Monitoring and Management of                           States
                                  Patients' Health Status and Medical Treatment
                                  Regimens

4/10/98        D420,446           Hand-Held Portable Medical Monitoring Device      Issued         United
                                                                                    2/8/2000       States

9/20/90        6,085,752          Method, apparatus and operating system for        Issued         United
                                  managing the admin. of medication treatment       7/11/2000      States
                                  regimens

10/22/97       6,102,855          Variable Capacity Medication Container and        Issued         United
                                  Labeling System for Medical Monitoring Device     8/15/00        States
</TABLE>

<PAGE>

                               INFORMEDIX PATENTS
                       FOREIGN (NON-UNITED STATES) PATENTS

<TABLE>
<CAPTION>
Date Filed       Ref. No.         Status               Country
----------       --------         ------               -------
<S>              <C>              <C>                  <C>
6/19/85          1,293,382        Issued 12/24/91      Canada
7/05/85          0172638B1        Issued 4/22/92       United Kingdom
7/05/85          0172638B1        Issued 4/22/92       Germany
7/05/85          0172638B1        Issued 4/22/92       Italy
7/05/85          0172638B1        Issued 4/22/92       France
3/30/86          60-145921          Issued 1993        Japan
 3/6/98        PCT 98/03933          Pending           Canada, Europe, Japan,
                                                       Australia, Mexico, North
                                                       Korea
</TABLE>

                     INFORMEDIX TRADEMARKS AND SERVICEMARKS
                             UNITED STATES TRADEMARK

                                  MEDI-MONITOR
                           Med-eMonitor(TM) (pending)
                     Real-Time Patient Information (pending)

<PAGE>

                                   SCHEDULE I

     a. PROVISIONAL PA TENT LIST

     Filing Date: 20010108

     A METHOD AND APPARATUS OF MASS CUSTOMIZATION OF INFORMATION DEVICE
FUNCTIONS AND FEATURES THROUGH SERVER ACCESS TO, OR DOWNLOADING OF,
SUBGROUP-SPECIFIC SOFTWARE APPLICATIONS

     Filing Date:20001 114

     METHOD, APPARATUS, AND OPERATING SYSTEM FOR PROVIDING DYNAMIC,
MASS-CUSTOMIZABLE, INTERACTIVE SCREENS AND VOICE PROMPTS FOR SELECTING MEDICAL
INFORMATION TO IMPROVE HEALTH OUTCOMES

     Filing Date: 20001019

     METHOD AND APPARATUS OF TRANSACTION-BASED MONITORING, CUSTOMER RELATIONS
MANAGEMENT, AND ACCOUNTING SYSTEMS

     Filing Date: 20000911

     METHOD AND APPARATUS OF ENHANCED SCIENTIFIC VALIDITY IN

     PHARMACEUTICAL ADVERTISEMENT CLAIMS AND DRUG PACKAGE INSERTS BASED UPON

     REAL-TIME CORRELATION OF MEDICATION COMPLIANCE INFORMATION WITH HEALTH
OUTCOMES INFORMATION

     Filing Date: 20000906

     METHOD AND APPARATUS OF STREAMING VIDEO AND PICTORIAL REPRESENTATIONS, TO
MONITOR AND ENHANCE MEDICATION COMPLIANCE, PHYSIOLOGIC STATUS, HEALTH STATUS,
AND PHARMACEUTICAL SALES

     Filing Date: 20000828

     METHOD AND APPARATUS FOR THE CREATION AND SELF-SELECTION OF MUSICAL ALARMS,
TO OPTIMIZE ADHERENCE TO MEDICATION REGIMENS AND MEDICAL TREATMENT PLANS

     Filing Date: 20000824

     METHOD AND APPARATUS OF PROVIDING PHARMACO-ECONOMIC ANALYSIS, BASED UPON
THE CORRELATION OF REAL-TIME MEASURES OF MEDICATION COMPLIANCE; PHYSIOLOGIC AND
HEALTH STATUS; AND GENOMIC, PROTEOMIC, AND PHENOTYPIC DATA.

<PAGE>

     Filing Date: 20000821

     METHOD AND APPARATUS OF PROVIDING SELF-SELECTED, SYNCHRONIZED,
DATABASE-LINKED MEDICAL MONITORS TO OUTPATIENTS AND THEIR CAREGIVERS

     Filing Date: 20000627

     METHOD AND APPARATUS OF PROVIDING REAL-TIME, RISK-STRATIFIED, TRIAGE AND
MEDICAL INTERVENTIONS, BASED UPON AN INTERNET-ENABLED PATIENT CARE MANAGEMENT
SYSTEM

     Filing Date: 20000526

     METHOD AND APPARATUS OF PROVIDING A REAL-TIME, TIME-AND-E VENT-DRIVEN
MEDICAL TREATMENT PLAN TO OUTPATIENTS AND THEIR CAREGIVERS

     Filing Date: 20000420

     METHOD AND APPARATUS OF MASS CUSTOMIZATION OF MEDICAL PROTOCOLS, TO MONITOR
AND MANAGE MEDICAL OUTPATIENTS

                                   SCHEDULE II
                                   -----------

          INFOR.MEDIX HAS NOT LICENSED ITS PATENTS TO ANY THIRD PARTIESExhibit 10.17

                           [Letterhead of InforMedix]

                                February 6, 2003

Rockwell Capital Partners, LLC
488 Madison Avenue, 8th Floor
New York, NY 10022
Attn: Robert DePalo

Dear Robert:

      The purpose of this letter is to clarify the sequence of transactions in
which Rockwell Capital Partners, LLC ("Rockwell") and/or affiliates of Rockwell
loaned money to InforMedix and converted a portion of the amount loaned into
equity of InforMedix. This letter sets forth the understanding and agreement
between InforMedix and Rockwell regarding such transactions. In consideration
thereof, the parties agree as follows:

     1.   On or about August 1, 2002, InforMedix issued Rockwell a convertible
          promissory note in a face amount of $150,000 (the "Rockwell Note").
          This note contemplated three loan advances by Rockwell to InforMedix
          of $50,000 each, of which only the initial $50,000 advance was made.

     2.   On or about August 1, 2002, Rockwell and/or its affiliates remitted
          $100,000 to JC Consulting in the name of, and on behalf of,
          InforMedix, and Rockwell is hereby representing that such payment was
          made in full. Although, a promissory note was never issued for such
          amount, it was intended that this amount (hereinafter referred to as
          the "JC Consulting Loan") be repaid to Rockwell on terms comparable to
          the Rockwell Note.

     3.   In connection with the merger of InforMedix, Inc. and InforMedix
          Acquisition Corp. on August 22, 2002, Rockwell was deemed to have
          converted $50,000 of the amount owed to it pursuant to the JC
          Consulting Loan into 4,700,000 shares of InforMedix common stock.
          There remains $50,000 outstanding on the JC Consulting Loan and
          InforMedix wishes to issue a convertible promissory note to Rockwell,
          dated as of the date of that loan, to evidence that $50,000
          obligation.

     4.   On or about September 5, 2002, Rockwell and InforMedix entered into an
          agreement with American United Global, Inc. ("AUGI") under which AUGI
          agreed to advance the $100,000 remaining to be advanced to InforMedix
          under the Rockwell Note. Pursuant to this agreement, InforMedix issued
          a convertible promissory note to AUGI in the amount of $100,000 and
          agreed by letter

<PAGE>

          agreement with Rockwell and AUGI to reduce the Rockwell Note to
          $50,000. InforMedix wishes to have Rockwell surrender and cancel the
          Rockwell Note so that InforMedix may issue a new promissory note to
          Rockwell, dated as of the date of that loan, in the principal amount
          of $50,000.

     5.   In lieu of issuing Rockwell a convertible promissory note dated as of
          August 1, 2002 for the $50,000 outstanding on the Rockwell Note and
          the $50,000 obligation remaining for the JC Consulting Loan, Rockwell
          wishes that InforMedix issue a convertible promissory note in the
          amount of $50,000 payable to Allied International Fund and a
          convertible promissory note in the amount of $50,000 payable to Old
          Oak Fund, which entities are affiliates of Rockwell.

          If the foregoing meets with your approval and properly reflects your
understanding of the terms and conditions agreed to by the parties, please so
indicate by signing below.

                                      Very truly yours,

                                      INFORMEDIX ACQUISITION CORP.

                                      By:  /s/ Bruce A. Kehr
                                          -------------------------------
                                      Bruce A. Kehr, M.D.
                                      Chairman and Chief Executive Officer

AGREED AND ACCEPTED:

ROCKWELL CAPITAL PARTNERS, LLC

By: /s/ Robert DePalo
    ----------------------------------------

Name:    Robert DePalo
         -----------------------------------

Title:  President
       -------------------------------------

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00048-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00048-of-00352.parquet"}]]